FindTrial
Sign In

Comparative Effect of Basti therapy of Ayurveda in chronic kidney disease treatment

A clinical study to evaluate the comparative effect of customised Basti and classical Basti in the management of chronic kidney disease (CKD): An exploratory trial - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/07/070318
Enrollment
50
Registered
2024-07-09
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N183- Chronic kidney disease, stage 3 (moderate)

Interventions

None listed

Sponsors

All India Institute of Ayurveda (AIIA)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of both genders having age group 21-65 yrs. with confirmed diagnosis of stage up to G3-B as per standard KDIGO-CRITERIA, not having undergone RRT were included. 2. Patients under controlled Diabetes and Hypertension with or without conventional medications.

Exclusion criteria

Exclusion criteria: 1. Patients suffering from Tuberculosis, Malignancy, Pregnancy and lactation, or any other systemic illness. 2. Uncontrolled diabetes and HTN 3. HIV-associated nephropathy and transplant allograph failure 4. Renal Artery stenosis. 5. Neoplasm of Kidney. 6. History of previous kidney transplant. 7. Patients of Congenital Renal Diseases like Autosomal dominant and Recessive Polycystic Kidney disease, Congenital Nephrotic syndrome, Alports syndrome, Fabrys disease and juvenile Nephronophthisis. 8. Patients with other added complications

Design outcomes

Primary

MeasureTime frame
Reduction in the values of KFT (Sr Creatinine, Blood urea, Serum Uric acid level) and to improve estimated Glomerular Filtration Rate (e-GFR)Timepoint: KFT assessed at Baseline, 15th, 30th 45th and 60th (AT), after 2-month FU. e-GFR assessed at BT, AT, after 2-month FU.—

Secondary

MeasureTime frame
1. To improve Hb%. 2. To reduce Albuminuria. 3. To improvement in signs and symptoms of CKD 4. Assessment of quality of life by-Kidney Disease Quality of Life Short Form (KDQOL-SF™) 5. To analyze electrolyte imbalance.Timepoint: 1. Hemoglobin assessed at BT, 15th, AT, after 2-month FU 2. Albuminuria assessed at BT, 15th, after AT, 2-month FU. 3. Signs and symptoms of CKD at BT, AT, after 2-monthsFU 4. Quality of life of patients at BT, AT, after 2-months FU 5. Sr Electrolyte assessed at BT, 15th, AT, after 2-month FU.—

Countries

India

Contacts

Public ContactDr Darshan Mohan Mahulkar

All India Institute of Ayurveda, New Delhi

drrkyadava@gmail.com9412148437

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026